
FLEXIBLE STRENGTH. PROVEN SUCCESS.

Demonstrated long-term durable clinical outcomes in complex aortoiliac occlusive disease (AIOD) treatment through **5 years.**

Sustained clinical effectiveness through 5 years:

- 89.5% primary patency and 96.1% primary assisted patency per lesion¹
- 89.1% freedom from target lesion revascularization (fTLR) per subject¹

This physician-initiated study enrolled 59 patients from 3 participating centers with patients followed out to **5 years**.



Kaplan-Meier graph of primary patency with number of lesions at risk.



DURABLE PATIENT BENEFIT VERSUS BASELINE AT 5 YEARS¹

of evaluated (n=28) patients improved ≥ 1 Rutherford category from baseline*,1

improvement in mean resting ankle-brachial index (ABI) (P < .001, .95 mean ABI)^{†,1}

3x improvement in median WIQ score sustained beyond 5 years in long-term follow-up cohort¹

	Pre-procedure	3 years	5 years [‡]
Walking distance	7 (N = 59)	25 (N = 39)	21 (N = 27)
Walking speed	3 (N = 59)	10 (N = 39)	9 (N = 27)
Stair climbing	3 (N = 50)	11 (N = 38)	9 (N = 27)

^{* 59} subjects participated and 28 were available through the end of the study at 5-year follow-up.



Reference

1. Holden A, Takele E, Hill A, et al. Long-Term Follow-up of Subjects With Iliac Occlusive Disease Treated With the Viabahn VBX Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy 2023;0(0). Doi:10.1177/15266028231165723



Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. R_{Only}

Products listed may not be available in all markets.

GORE, Together, improving life, VBX, VBX FLEX, VIABAHN and designs are trademarks of W. L. Gore & Associates. © 2024 W. L. Gore & Associates GmbH 24PL2041-EN01 MAY 2024



^{† (}P < .001) Statistically significant change from pre-procedure.

[‡] Median follow-up of 6.6 years.